# Matthew Gline

> Matthew Gline is a startup investor at Roivant Sciences. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Roivant Sciences](https://shizune.co/investors/profile/roivant-sciences)
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/matthewgline/

Matthew Gline is a startup investor at Roivant Sciences. Matthew Gline is Chief FMatthew Gline has served as Chief Financial Officer of Roivant Sciences since September 2017. Mr. Gline joined Roivant in March 2016 and previously served as Senior Vice President, Finance and Business Operations. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, wherehe focused on technology and data strategy.Matthew Gline has served as Chief Financial Officer of Roivant Sciences since September 2017. Mr. Gline joined Roivant in March 2016 and previously served as Senior Vice President, Finance and Business Operations. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

## About Roivant Sciences

VC Fund · New York, United States

Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech andhealthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.

5 contacts available at Roivant Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Alex Gasner | Executive Vice President | https://shizune.co/investors/profile/alex-gasner-ae3b |
| Frank Torti | Vant Chair | https://shizune.co/investors/profile/frank-torti |
| Matthew Gline | Chief Executive Officer | https://shizune.co/investors/profile/matthew-gline |
| Mayukh Sukhatme | Chief Investment Officer & President | https://shizune.co/investors/profile/mayukh-sukhatme |
| Benjamin Zimmer | President, Roivant Health | https://shizune.co/investors/profile/benjamin-zimmer-85fd |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co